Literature DB >> 28877059

Choriocarcinoma in Women: Analysis of a Case Series With Genotyping.

Johanna Savage1, Emily Adams, Emanuela Veras, Kathleen M Murphy, Brigitte M Ronnett.   

Abstract

Choriocarcinoma is an uncommon malignant neoplasm, which can be either gestational or nongestational in origin. Distinction of these subtypes has prognostic and therapeutic implications. Twenty-two tumors were genotyped using polymerase chain reaction amplification of 15 short tandem repeat loci and the amelogenin locus (XY determination). DNA patterns from tumor and maternal tissue, as well as villous tissue from any available prior or concurrent gestation, were compared, to determine gestational versus nongestational nature (containing vs. lacking a paternal chromosome complement, respectively) and the relationship between the tumor and any prior or concurrent gestation. Nineteen tumors were gestational. Of these, 14 were purely androgenetic/homozygous XX: 6 uterine tumors with a concurrent or prior genetically related complete hydatidiform mole (CHM), 4 uterine tumors without an accompanying villous component, 1 uterine cornual tumor separate from a genetically distinct second trimester intrauterine placenta, 1 ectopic ovarian tumor separate from a genetically distinct third trimester intrauterine placenta, and 2 ectopic fallopian tube tumors. Five gestational tumors were biparental: 3 (2 XX, 1 XY) intraplacental choriocarcinomas genetically related to the placenta and 2 uterine tumors without accompanying placental tissue after term deliveries (1 XX 4 weeks postpartum and 1 XYY with allelic imbalances 1 year postpartum; prior placentas not available for analysis). Three tumors were nongestational: all XX with allelic imbalances; 2 ovarian, 1 pelvic. Gestational choriocarcinoma can be androgenetic or biparental. Most are androgenetic/homozygous XX, often associated with a genetically related concurrent or prior CHM, and thus of molar-associated type. These findings support that homozygous XX CHMs are associated with some risk of significant gestational trophoblastic disease. Intraplacental choriocarcinomas are biparental and genetically related to the placenta. Biparental choriocarcinoma detected in a postpartum uterine sample is consistent with undetected intraplacental choriocarcinoma. Eutopic or ectopic androgenetic choriocarcinoma separate from a concurrent intrauterine placenta is not derived from intraplacental tumor and is consistent with either a form of dispermic twin gestation (molar-type choriocarcinoma and coexistent nonmolar fetus) or origin from an antecedent molar pregnancy. While fallopian tube tumors are usually gestational, tumors in other sites (ovary, pelvis) can be nongestational and should not be assumed to be metastatic from a regressed or occult intrauterine or intraplacental gestational tumor.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28877059     DOI: 10.1097/PAS.0000000000000937

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  14 in total

1.  A pilot study comparing the genetic molecular biology of gestational and non-gestational choriocarcinoma.

Authors:  Cordelle Lazare; Wenhua Zhi; Jun Dai; Canhui Cao; Rajiv Rai Sookha; Ling Wang; Yifan Meng; Peipei Gao; Ping Wu; Juncheng Wei; Junbo Hu; Peng Wu
Journal:  Am J Transl Res       Date:  2019-11-15       Impact factor: 4.060

Review 2.  Genotyping diagnosis of gestational trophoblastic disease: frontiers in precision medicine.

Authors:  Natalia Buza; Pei Hui
Journal:  Mod Pathol       Date:  2021-06-04       Impact factor: 7.842

Review 3.  A review on management of gestational trophoblastic neoplasia.

Authors:  Seyedeh Reyhaneh Yousefi Sharami; Elham Saffarieh
Journal:  J Family Med Prim Care       Date:  2020-03-26

4.  Ovarian Intermediate Trophoblastic Tumors: Genotyping Defines a Distinct Category of Nongestational Tumors of Germ Cell Type.

Authors:  Deyin Xing; Minghao Zhong; Fei Ye; Michael T O'Malley; Shaotiao Li; Russell Vang; Brigitte M Ronnett
Journal:  Am J Surg Pathol       Date:  2020-04       Impact factor: 6.298

5.  Gestational Tubal Choriocarcinoma Presenting as a Pregnancy of Unknown Location following Ovarian Induction.

Authors:  Lawrence Hsu Lin; Koji Fushida; Eliane Azeka Hase; Regina Schultz; Laysa Manatta Tenorio; Fabricia Andrea Rosa Madia; Evelin Aline Zanardo; Leslie Domenici Kulikowski; Rossana Pulcineli Vieira Francisco
Journal:  Case Rep Obstet Gynecol       Date:  2018-05-03

6.  Using short tandem repeat analysis for choriocarcinoma diagnosis: a case series.

Authors:  Xiaofei Zhang; Kai Yan; Jianhua Chen; Xing Xie
Journal:  Diagn Pathol       Date:  2019-08-17       Impact factor: 2.644

7.  A poor prognostic metastatic nongestational choriocarcinoma of the ovary: a case report and the literature review.

Authors:  Kimihiro Nishino; Eiko Yamamoto; Yoshiki Ikeda; Kaoru Niimi; Toshimichi Yamamoto; Hiroaki Kajiyama
Journal:  J Ovarian Res       Date:  2021-04-22       Impact factor: 4.234

8.  Refined diagnosis of hydatidiform moles with p57 immunohistochemistry and molecular genotyping: updated analysis of a prospective series of 2217 cases.

Authors:  Deyin Xing; Emily Adams; Jialing Huang; Brigitte M Ronnett
Journal:  Mod Pathol       Date:  2020-10-06       Impact factor: 7.842

Review 9.  Transmission of a TP53 germline mutation from unaffected male carrier associated with pediatric glioblastoma in his child and gestational choriocarcinoma in his female partner.

Authors:  Jennifer A Cotter; Linda Szymanski; Catherine Karimov; Lara Boghossian; Ashley Margol; Girish Dhall; Benita Tamrazi; G Isaac Varaprasathan; David M Parham; Alexander R Judkins; Jaclyn A Biegel
Journal:  Cold Spring Harb Mol Case Stud       Date:  2018-04-02

10.  Clinical features of a Chinese female nongestational choriocarcinoma cohort: a retrospective study of 37 patients.

Authors:  Yuming Shao; Yang Xiang; Fang Jiang; Boju Pan; Xirun Wan; Junjun Yang; Fengzhi Feng; Tong Ren; Jun Zhao
Journal:  Orphanet J Rare Dis       Date:  2020-11-18       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.